Cargando…
A case of synchronous multiple primary lung adenocarcinomas harboring epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement successfully treated with combination of osimertinib and alectinib
Synchronous multiple primary lung cancers (SMPLC) should be distinguished from intrapulmonary metastasis to define the optimal treatment approach. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are typically mutually exclusive and the co-existen...
Autores principales: | Inoue, Yukihisa, Matsubara, Osamu, Ohira, Yumi, Endo, Satoshi, Jinn, Yasuto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348148/ https://www.ncbi.nlm.nih.gov/pubmed/34401266 http://dx.doi.org/10.1016/j.rmcr.2021.101418 |
Ejemplares similares
-
Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
por: Hayashi, Nobuyoshi, et al.
Publicado: (2017) -
Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
por: Kimura, Tatsuo, et al.
Publicado: (2016) -
Control of brain metastases with alectinib in anaplastic lymphoma kinase‐rearranged lung cancer
por: Kwok, Wang Chun, et al.
Publicado: (2017) -
Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report
por: SUN, QIONG, et al.
Publicado: (2014) -
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)